Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

192 result(s)

  • ENT/Head and Neck Cancers
    Paris
    219885 GALAXIES H&N-202
    A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    CHRISTOPHE LE TOURNEAU

  • Colorectal cancer
    Saint-Cloud
    ADAGE - Prodige 34
    Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.

  • Sarcomas
    Paris
    ADCT-601-102
    A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

    SARAH WATSON

  • Saint-Cloud
    AIPAC
    AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

    ETIENNE BRAIN

  • Lung cancer
    Paris
    AK112-301-HARMONi
    A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-2
    Analysis of Circulating Tumor Markers in Blood

    FRANCOIS-CLEMENT BIDARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-4 (IC 2020-11)
    Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

    LUC CABEL, FRANCOIS-CLEMENT BIDARD

  • Paris, Saint-Cloud
    ALCYTA (IC 2020-12)
    Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA

    NICOLAS GIRARD

  • Saint-Cloud
    ALPHABET
    Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    AMEBICA - Prodige 38
    Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.

  • Saint-Cloud
    AML LI-1
    A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME

    JACQUES VARGAFTIG

  • Saint-Cloud
    APACaP
    Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

  • Saint-Cloud
    AcSé Pembrolizumab
    Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.

    CAROLE SOUSSAIN

  • Saint-Cloud
    AcSé Vemurafenib
    Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

    ETIENNE BRAIN

  • Sarcomas
    Paris
    BFR ESS 01
    Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS

    SOPHIE PIPERNO-NEUMANN

  • Paris
    BGB-A317-A3055-101
    A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Lung cancer
    Paris
    BGB-LC-201
    A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI 1479-0008 (BEAMION LUNG 2)
    Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled,;multi-centre trial evaluating orally administered;BI 1810631 compared with standard of care as first-line treatment;in patients with unresectable, locally advanced or metastatic nonsquamous;non-small cell lung cancer harbouring HER2 tyrosine;kinase domain mutations.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI1438-0009 (DAREON 9)
    DAREONTM-9: A Phase Ib open-label dose escalation and dose;confirmation safety study of intravenous BI 764532 in;combination with topotecan for the treatment of patients with;small cell lung cancer

    PAULINE DU RUSQUEC

  • Bladder cancer
    Paris
    BLAD-RAD01 (GETUG-AFU V07)
    Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial.

    GILLES CREHANGE

  • Saint-Cloud
    BLOCAGE 01
    Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line

    CAROLE SOUSSAIN

  • Paris
    BNT113-01
    A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

    CHRISTOPHE LE TOURNEAU

  • Saint-Cloud
    BO25430
    AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY.

    FLORENCE LEREBOURS

  • Breast cancer
    Paris
    BRAINSTORM
    A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program

    EDITH BORCOMAN

  • Lung cancer
    Paris
    BRIDGE (D9106C00002)
    A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

    NICOLAS GIRARD

  • Saint-Cloud
    BYLieve (CBYL719X402)
    A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

    FLORENCE LEREBOURS

  • Leukemia
    Saint-Cloud
    Backbone Inter-Group-1 (BIG-1)
    Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

    JACQUES VARGAFTIG

  • Lymphoma
    Saint-Cloud
    CA-4948-101
    An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.

    CAROLE SOUSSAIN

  • Saint-Cloud
    CANTO (Saint-Cloud)
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

    FLORENCE LEREBOURS

  • Childhood and adolescent cancers
    Paris
    CDRB436G2401
    An open label, multi-center roll-over study to assess longterm;effect in pediatric patients treated with Tafinlar;(dabrafenib) and/or Mekinist (trametinib)

    ISABELLE AERTS GAJDOS

1 ...7
>